Michael Okunewitch
Stock Analyst at Maxim Group
(1.47)
# 3,507
Out of 5,006 analysts
28
Total ratings
32%
Success rate
-2.58%
Average return
Main Sectors:
Stocks Rated by Michael Okunewitch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CTOR Citius Oncology | Upgrades: Buy | $6 | $1.86 | +222.58% | 3 | Sep 23, 2025 | |
| ANEB Anebulo Pharmaceuticals | Downgrades: Hold | n/a | $2.33 | - | 3 | Jul 23, 2025 | |
| HCWB HCW Biologics | Maintains: Buy | $120 → $35 | $4.10 | +754.70% | 2 | May 29, 2025 | |
| RADX Radiopharm Theranostics | Initiates: Buy | $12 | $7.09 | +69.25% | 1 | May 1, 2025 | |
| CMMB Chemomab Therapeutics | Maintains: Buy | $16 → $28 | $2.86 | +879.02% | 2 | Feb 20, 2025 | |
| MYNZ Mainz Biomed | Initiates: Buy | $14 | $1.63 | +757.37% | 1 | Feb 14, 2025 | |
| LCTX Lineage Cell Therapeutics | Maintains: Buy | $5 → $3 | $1.71 | +75.44% | 1 | Jan 10, 2025 | |
| OCGN Ocugen | Initiates: Buy | $4 | $1.82 | +119.78% | 1 | Oct 15, 2024 | |
| FBLG FibroBiologics | Initiates: Buy | $12 | $0.55 | +2,082.21% | 1 | Sep 24, 2024 | |
| LGVN Longeveron | Maintains: Buy | $15 → $6 | $0.79 | +658.15% | 2 | Aug 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $3 → $12 | $0.84 | +1,328.74% | 2 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $1.92 | +1,150.00% | 1 | Oct 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $108 → $18 | $2.74 | +556.91% | 3 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $2,025 | $2.56 | +79,001.56% | 1 | Apr 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $17.55 | +42.45% | 1 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $1.53 | +292.16% | 1 | Sep 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $5.47 | +357.04% | 1 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $100 | $1.33 | +7,418.80% | 1 | Nov 30, 2021 |
Citius Oncology
Sep 23, 2025
Upgrades: Buy
Price Target: $6
Current: $1.86
Upside: +222.58%
Anebulo Pharmaceuticals
Jul 23, 2025
Downgrades: Hold
Price Target: n/a
Current: $2.33
Upside: -
HCW Biologics
May 29, 2025
Maintains: Buy
Price Target: $120 → $35
Current: $4.10
Upside: +754.70%
Radiopharm Theranostics
May 1, 2025
Initiates: Buy
Price Target: $12
Current: $7.09
Upside: +69.25%
Chemomab Therapeutics
Feb 20, 2025
Maintains: Buy
Price Target: $16 → $28
Current: $2.86
Upside: +879.02%
Mainz Biomed
Feb 14, 2025
Initiates: Buy
Price Target: $14
Current: $1.63
Upside: +757.37%
Lineage Cell Therapeutics
Jan 10, 2025
Maintains: Buy
Price Target: $5 → $3
Current: $1.71
Upside: +75.44%
Ocugen
Oct 15, 2024
Initiates: Buy
Price Target: $4
Current: $1.82
Upside: +119.78%
FibroBiologics
Sep 24, 2024
Initiates: Buy
Price Target: $12
Current: $0.55
Upside: +2,082.21%
Longeveron
Aug 27, 2024
Maintains: Buy
Price Target: $15 → $6
Current: $0.79
Upside: +658.15%
Mar 5, 2024
Maintains: Buy
Price Target: $3 → $12
Current: $0.84
Upside: +1,328.74%
Oct 5, 2023
Initiates: Buy
Price Target: $24
Current: $1.92
Upside: +1,150.00%
Aug 9, 2023
Maintains: Buy
Price Target: $108 → $18
Current: $2.74
Upside: +556.91%
Apr 12, 2023
Initiates: Buy
Price Target: $2,025
Current: $2.56
Upside: +79,001.56%
Dec 22, 2022
Initiates: Buy
Price Target: $25
Current: $17.55
Upside: +42.45%
Sep 28, 2022
Initiates: Buy
Price Target: $6
Current: $1.53
Upside: +292.16%
Nov 30, 2021
Initiates: Buy
Price Target: $25
Current: $5.47
Upside: +357.04%
Nov 30, 2021
Initiates: Buy
Price Target: $100
Current: $1.33
Upside: +7,418.80%